酪氨酸激酶抑制剂(tyrosine kinase inhibitor,TKI)使慢性粒细胞白血病(chronic myeloid leukemia,CML)疗效取得了划时代的改变,也成为国际国内CML治疗的一线选择。近年陆续有更多的TKI上市,目前国内上市的3种TKI包括一代药物伊马替尼和二代药物尼洛替尼及达沙替尼。中国CML诊治指南2016年版TKI一线选择包括伊马替尼和尼洛替尼~([1]),国际上3种TKI均已成为 Tyrosine kinase inhibitor (TKI) has made epoch-making changes in the efficacy of chronic myeloid leukemia (CML), and has also become the first choice of international and domestic CML therapy. There have been more TKIs listed in succession in recent years. Currently, the three TKIs listed in China include the first-generation imatinib and the second-generation drugs nilotinib and dasatinib. The first-line TKIs for 2016 CML Review and Treatment Guideline include imatinib and nilotinib ~ ([1]). Three international TKIs have become